CT

:   computed tomography

ICI

:   immune checkpoint inhibitor

irAE

:   immune‐related adverse event

mTOR

:   mammalian target of rapamycin

PD‐1

:   programmed cell death‐1

RCC

:   renal cell carcinoma

RRP

:   radiation recall pneumonitis

RRR

:   radiation recall reaction

Keynote messageTo our knowledge this is the first case of nivolumab‐induced RRP in a patient with RCC. Most physicians other than respiratory care specialists are not familiar with RRP. Our findings indicate that all physicians should consider the risk of RRP during treatment with ICIs in patients with a history of thoracic radiotherapy and update the patient about the same.

Introduction {#iju512032-sec-0005}
============

Nivolumab is an anti‐PD‐1 antibody that has been approved as an ICI for cancer therapy. Nivolumab for RCC improved overall survival in the Checkmate 025 trial.

Patients treated with ICIs can develop several adverse events based on an autoimmune etiology; these are called irAEs. IrAEs are quite different from adverse events caused by conventional cytotoxic agents, and they can potentially affect any organ. In particular, pneumonitis is a notable irAE that accounted for three deaths in an early‐phase study of a PD‐1 inhibitor.[1](#iju512032-bib-0001){ref-type="ref"}

RRP is a RRR that can occur after radiotherapy followed by administration of various anticancer drugs. RRR is characterized by an acute inflammatory reaction in a previously irradiated area. It can develop several weeks to months after radiotherapy completion.[2](#iju512032-bib-0002){ref-type="ref"}, [3](#iju512032-bib-0003){ref-type="ref"}

Because RRP can have severe consequences,[4](#iju512032-bib-0004){ref-type="ref"}, [5](#iju512032-bib-0005){ref-type="ref"}, [6](#iju512032-bib-0006){ref-type="ref"}, [7](#iju512032-bib-0007){ref-type="ref"}, [8](#iju512032-bib-0008){ref-type="ref"}, [9](#iju512032-bib-0009){ref-type="ref"} physicians should be aware of this complication while administering ICIs after radiation therapy. However, reports of ICI‐induced RRP are limited.[10](#iju512032-bib-0010){ref-type="ref"}

Here we report a rare case of nivolumab‐induced RRP in a patient with RCC, in which steroid therapy was effective.

Case presentation {#iju512032-sec-0006}
=================

A 69‐year‐old woman visited our hospital because of unexplained fatigue. Thoracic, abdominal, and pelvic CT showed several pulmonary lesions, with the largest having a maximum diameter of 2 cm. In addition, there were several rib masses, enlarged mediastinal lymph nodes, and a 9‐cm mass resembling a malignancy in the left kidney. She underwent cytoreductive nephrectomy in July 2013. Histological examination revealed clear cell RCC.

In August 2013, first‐line sunitinib was initiated. However, she still experienced fatigue, and the treatment was discontinued. Three tyrosine kinase inhibitors and two mTOR inhibitors were administered and discontinued because of adverse events, such as fatigue and anorexia, with a 3--6‐month duration. In January 2016, palliative radiotherapy was administered for pain control; 30 Gy in 10 fractions was delivered to the ribs. In October 2016, treatment with nivolumab (3 mg/kg) was initiated. Three days after the initial administration, she presented with dyspnea, cough, and low‐grade fever. There was no increase in KL‐6 or SP‐D. CT showed a right lung consolidation with ground glass opacities in a previously irradiated area (Fig. [1](#iju512032-fig-0001){ref-type="fig"}). At that time, she was not receiving any drug, other than nivolumab, that could induce interstitial pneumonia. Accordingly, she was diagnosed with pneumonitis caused by nivolumab and radiotherapy. Oral prednisolone (1 mg/kg) was immediately initiated, and was discontinued after 4 months with gradual tapering. The patient\'s symptoms rapidly resolved, and follow‐up chest CT 4 months after nivolumab cessation showed interval resolution of the consolidation in the right lung and persistent tumor shrinkage (Fig. [2](#iju512032-fig-0002){ref-type="fig"}).

![Radiation field and representative images obtained before nivolumab treatment and at the time of nivolumab‐induced RRP in a 69‐year‐old woman with RCC.](IJU5-2-30-g001){#iju512032-fig-0001}

![Chest CT images obtained at the time of nivolumab‐induced RRP and 4 months after the cessation of nivolumab in a 69‐year‐old woman with RCC. The image obtained at 4 months after nivolumab cessation shows interval resolution of consolidation in the right lung, along with persistent tumor shrinkage.](IJU5-2-30-g002){#iju512032-fig-0002}

Discussion {#iju512032-sec-0007}
==========

Nivolumab is an IgG4 monoclonal antibody against PD‐1 that has increased the survival rate for patients with advanced RCC.[11](#iju512032-bib-0011){ref-type="ref"} Nivolumab‐induced adverse events differ from those caused by conventional cytotoxic chemotherapy; they include common side effects such as fatigue as well as distinct irAEs.[12](#iju512032-bib-0012){ref-type="ref"} IrAEs are triggered by activation of the autoimmune system by T cell activation and include dermatitis, endocrinopathies, and pneumonitis. Pneumonitis constitutes the major and most common toxicity caused by ICIs.[1](#iju512032-bib-0001){ref-type="ref"}, [10](#iju512032-bib-0010){ref-type="ref"}, [12](#iju512032-bib-0012){ref-type="ref"} Therefore, with the increasing use of ICIs, diagnosis and proper management of irAEs is important.

When radiotherapy is followed by the administration of an anticancer agent, the subclinical damage caused by irradiation is unmasked and clinically manifests as RRR. The skin is the major site of RRR, which is known as RRP when it occurs in previously irradiated lungs. RRP induced by chemotherapy is diagnosed on the basis of previous thoracic radiotherapy, radiographic abnormalities, and the clinical presentation. Symptoms appear within days or weeks after administration of the antitumor agent, and RRP can develop several weeks to months after radiotherapy completion.[2](#iju512032-bib-0002){ref-type="ref"}, [3](#iju512032-bib-0003){ref-type="ref"}, [4](#iju512032-bib-0004){ref-type="ref"}, [5](#iju512032-bib-0005){ref-type="ref"}, [13](#iju512032-bib-0013){ref-type="ref"} Antitumor agents that can cause RRP include anthracyclines, taxanes, gefitinib, erlotinib, gemcitabine, and sunitinib.[5](#iju512032-bib-0005){ref-type="ref"}, [6](#iju512032-bib-0006){ref-type="ref"}, [7](#iju512032-bib-0007){ref-type="ref"}, [8](#iju512032-bib-0008){ref-type="ref"}, [9](#iju512032-bib-0009){ref-type="ref"} For this patient, (i) no imaging and clinical symptoms were observed for 9 months after radiotherapy (radiation pneumonitis typically occurs within 6 months after radiotherapy); (ii) acute interstitial pneumonia began 3 days after nivolumab administration; (iii) the damaged area was consistent with the radiation field; (iv) the patient exhibited improvement upon PSL treatment after discontinuation of nivolumab; and (v) the patient had not been treated with other suspect drugs. From these points, the patient was diagnosed with RRP.

The etiology of RRR remains unknown. One hypothesis is that the precipitating agent participates in lethal damage accumulated by the stem cell population in a previously irradiated area.[14](#iju512032-bib-0014){ref-type="ref"} Another hypothesis constitutes hypersensitivity to cytotoxic drugs by radiation‐induced injury.[8](#iju512032-bib-0008){ref-type="ref"}

The management of RRR depends on the severity of symptoms. Withdrawal of the administered agents may lead to spontaneous improvement in RRR in some cases,[3](#iju512032-bib-0003){ref-type="ref"} while steroids may be needed in patients with severe pneumonitis. Ding *et al*. reported relief of symptoms and radiological chest abnormalities after withdrawal of the administered agent, combined with steroid administration in all 12 patients with RRP.[4](#iju512032-bib-0004){ref-type="ref"}

Although RRP occurred in our case, it showed a significant response against pulmonary metastasis from RCC. In previous studies, irAEs were associated with a durable response to ICIs in melanoma patients.[15](#iju512032-bib-0015){ref-type="ref"}, [16](#iju512032-bib-0016){ref-type="ref"} Moreover, immunotherapy‐related thyroid dysfunction and dermatitis have been associated with a clinical benefit of ICIs in patients with nonsmall cell lung cancer.[17](#iju512032-bib-0017){ref-type="ref"}, [18](#iju512032-bib-0018){ref-type="ref"}, [19](#iju512032-bib-0019){ref-type="ref"} Moreover, pneumonitis has been associated with a clinical benefit.[20](#iju512032-bib-0020){ref-type="ref"} Further studies should investigate the relationship between pneumonitis and therapeutic effects in patients with RCC.

To our knowledge, this is the first case of nivolumab‐induced RRP in a patient with RCC. Most physicians other than respiratory care specialists are not familiar with RRP. Our findings indicate that all physicians should consider the risk of RRP during treatment with ICIs in patients with a history of thoracic radiotherapy.
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